Clinical trial

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07670650

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-09-01

PhasePHASE3

Study timeline

Study start (estimated)2026-09-01Date precision: day

Registry last updated2026-06-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 1 Diabetes (T1D)unresolved

Interventions

SAB-142DRUG

PlaceboDRUG

Sponsors & collaborators

University of Floridalead sponsor

SAb Biotherapeutics, Inc.collaborator

Breakthrough T1Dcollaborator

Mapped research locations

San FranciscoCalifornia, United States1 IndianapolisIndiana, United States1 AuroraColorado, United States1 GainesvilleFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07670650 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.